Pharmacology
DrugBankDescription
Pipradrol (Meratran) was initially developed in the 1950s as an antidepressant, however, the adverse effects associated with its use and its abuse potential led to its withdrawal and international regulation . Pipradrol was made illegal in many countries in 1970s because of its potential for abuse. It is currently classified under the Misuse of Drugs Act as a Class C substance . Experimentation with the drug and its derivatives for recreational purposes has led to many cases of acute toxicity and has been linked to three fatalities. The social and in particular acute clinical harms of pipradrol derivatives have led to their control under the Misuse of Drugs Act 1971 in the UK in 2012 . Interestingly, this drug has been studied for bactericidal properties, however, is not currently, used for this purpose . In addition to this, it has shown favorable effects in postpartum depressive symptoms .
Mechanism of Action
Pipradrol and pipradrol derivatives are norepinephrine and dopamine reuptake inhibitors . In a pharmacokinetic study, it was shown that pipradrol conditioned place preference (CPP) was blocked by selective D1 dopamine antagonist, implicating that a rewarding effect of pipradrol may involve the activation of D1 dopamine receptors. Pipradrol has a definite cerebral stimulating effect without affecting the blood pressure or respiration and has been used to counteract post-anaesthetic and chlorpromazine depression in man. Structurally related to phenylmethylamphetamine, a potent stimulant with a long half-life, pipradrol differs from amphetamine in that its action is more intense at higher centers, it does not exhibit pressor activity, there is no post-excitement depression, and this drug does not decrease appetite, as occurs with amphetamine .
Pharmacodynamics
Pipradrol (Meratran) is a psychoactive agent and a central nervous system stimulant that has proven useful in the field of psychiatry . Pipradrol was initially used as an adjunct in the dietary management of obesity as well as for the management of dementia symptoms. Numerous reports have been made on the properties of pipradrol, demonstrating its favorable effects in the treatment of depression and fatigue in addition to a variety of other conditions including narcolepsy, spasmodic torticollis, schizophrenia and in geriatric practice .
Metabolism
Rapidly metabolized, and not found in plasma approximately 4 hours post administration .
Toxicity
Toxicity Data: Oral LD50 (rat): 180 mg/kg; Oral LD50 (mouse): 120 mg/kg; Oral LD50 (rabbit): 180 mg/kg . The toxicity of this drug is dependent on the dose ingested, and is owed to its central nervous stimulant activity , . Overdoses of pipradrol hydrochloride cause nausea, anxiety, insomnia and abdominal pain, however, these symptoms often disappear when the drug is withdrawn. In severe cases, convulsions may occur , . This drug is contraindicated in anxiety, psychosis states, and schizophrenia, as it can worsen these symptoms. Hallucinations have been reported after taking this drug . Over the last decade there has been greater use of novel psychoactive substances (‘legal highs’) across Europe and the United States, including increasing frequency of reports of diphenylprolinol (D2PM) and desoxypipradrol (2-DPMP) use . There are increasing reports that D2PM (desoxy analogue of pipradrol) and 2-DPMP (a pyrrolidine analogue of pipradrol) are used in Europe as drugs of abuse. 2-DPMP has sympathomimetic properties similar to cocaine and, in addition, prolonged and clinically significant neuropsychiatric symptoms have been reported . The binding and activity of D2PM at the dopamine re-uptake transporter, is also similar to cocaine, though it appears that D2PM has less potent biological activity .
Indication
Used to manage fatigue and depression , , , . Used as an adjunct therapy in the management of obesity .
Elimination
Quickly excreted in the urine (3.5%) and stool (5%) .
Receptor Profile
Receptor Actions
Receptor Binding
History & Culture
Pipradrol was developed in the United States during the 1940s and received its patent in 1953. By the mid-1950s, it had entered the pharmaceutical market under the brand name Meratran, primarily positioned as an antidepressant. Its clinical utility expanded to include adjunct treatment for a range of conditions such as obesity, senile dementia symptoms, attention deficit hyperactivity disorder, narcolepsy, and even schizophrenia. The compound's relatively mild stimulant profile compared to more potent alternatives contributed to a favorable safety record, making it suitable for these varied therapeutic applications. Commercial preparations included Meratran tablets and Alertonic liquid, with the latter being marketed in Australia. Despite its therapeutic promise, growing concerns regarding abuse potential led to pipradrol's withdrawal from widespread medical use and subsequent international regulation during the late 1970s. This occurred alongside the scheduling of numerous other substances with documented histories of misuse. The compound was placed into controlled substance categories across multiple jurisdictions, though its comparatively moderate stimulant effects resulted in less restrictive classifications than those applied to stronger stimulants. Today, pipradrol has become an obscure pharmaceutical largely forgotten as a recreational substance. Its primary contemporary relevance lies in scientific research, where it occasionally serves as a reference compound for evaluating the pharmacological properties of other stimulant drugs.
Effect Profile
CuratedStrong euphoria and anxiety/jitters with moderate focus and stimulation
Tolerance & Pharmacokinetics
drugs.wikiTolerance Decay
No formal human tolerance kinetics identified for pipradrol. Pattern is inferred from stimulant class: repeated frequent dosing over 1–3 days noticeably reduces effect, with partial reversal after several days abstinence; full return toward baseline typically within 1–2 weeks. Treat as anecdotal/theoretical and avoid back-to-back days to limit escalation.
Cross-Tolerances
Legal Status
| Country | Status | Notes |
|---|---|---|
| United Kingdom | Class C | Controlled under the Misuse of Drugs Act 1971. Pipradrol and its derivatives were specifically brought under control in 2012 due to social and acute clinical harms associated with their use. Class C substances carry penalties of up to 2 years imprisonment for possession and up to 14 years for supply. |
| United States | Schedule IV | Controlled under the Controlled Substances Act. Banned from the late 1970s due to its abuse potential. Schedule IV classification indicates accepted medical use with lower abuse potential relative to Schedule III substances. |
Harm Reduction
drugs.wikiMechanism: pipradrol and its congeners act predominantly as norepinephrine–dopamine reuptake inhibitors, which aligns with stimulation, insomnia, tachycardia, and anxiety at higher doses. Pharmacokinetic notes indicate rapid absorption and rapid plasma clearance with drug not detectable ~4 hours post-dose, yet central stimulation can outlast plasma presence, so timing and avoiding redosing are critical. Historical products (Meratran) contained 1 mg tablets, underscoring high potency and the need for milligram-accurate measurement or volumetric dosing. Overdose/overuse has been associated with anxiety, insomnia, abdominal discomfort, and in severe cases convulsions; individuals with psychosis, schizophrenia, or significant anxiety disorders should avoid due to exacerbation risk. Combining with MAOIs is dangerous with stimulant-class agents; mixing with other stimulants increases cardiovascular and neurotoxic stress and strongly elevates insomnia/psychosis risk. Tramadol and bupropion both lower the seizure threshold and have adverse interaction reports with stimulants; avoid. Because pipradrol-family powders have been mis-sold or confused with far longer-acting analogues (e.g., 2‑DPMP), confirm identity via reagent plus laboratory drug-checking when possible (GC/MS or FTIR); do not assume vendor labels are accurate. Insufflation provides no safety advantage, increases local harm, and may promote compulsive redosing; oral administration allows more controlled onset. Dose early in the day, maintain hydration and nutrition, and schedule a buffer for sleep; do not stack sedatives to ‘force’ sleep, as this can create risky polydrug situations.
References
Data Sources
Cited References
Drugs.wiki References
- Drug Users Bible: Pipradrol (dose, duration, safety framing)
- DrugBank DB11584: Pipradrol — NDRI mechanism; PK notes (rapid absorption/clearance; plasma ~4 h); contraindications/overdose features
- TripSit Drug Combination Chart announcements (general stimulant+MAOI danger; combo caution)
- TripSit Wiki: Adderall page (stimulant cautions; tramadol interaction and seizure-risk context)
- Erowid/DrugsData: Project overview (benefits of confirmatory GC/MS drug checking)
- Reddit r/ObscureDrugs: Meratran (1 mg pipradrol HCl tablets) photo post (historical potency context)